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Background: Establishing Total Body Irradiation (TBI) using Helical Tomotherapy (HT) to gain better control over
dose distribution and homogeneity and to individually spare organs at risk. Because of their limited body length
the technique seems especially eligible in juvenile patients.
Patients and methods: The cohort consisted of 10 patients, 6 female and 4 male, aged 4 - 22 y with acute
lymphoblastic- (ALL) or acute myeloic leukemia (AML). All patients presented with high risk disease features. Body
length in treatment position ranged from 110–180 cm. Two Gy single dose was applied BID to a total dose of
12 Gy. Dose volume constraint for the PTV was 95% dose coverage for 95% of the volume. The lungs were spared
to a mean dose of [less than or equal to] 10 Gy. Patients were positioned in a vac-loc bag in supine position with a
3-point head mask.
Results: Average D95 to the PTV was 11.7 Gy corresponding to a mean coverage of the PTV of 97.5%. Dmean for
the lungs was 9.14 Gy. Grade 3–4 side effects were not observed.
Conclusions: TBI using HT is feasible and well tolerated. A benefit could be demonstrated with regard to dose
distribution and homogeneity and the selective dose-reduction to organs at risk.Introduction
Among the downsides of classic TBI are the long applica-
tion time, non-conformality of beam-application with the
inability to individually spare organs at risk (OARs) and
hence – its` acute and late toxicity [1-5]. With the devel-
opment and clinical use of highly conformal radiation
technologies such as Helical Tomotherapy™ [6-8] different
working groups have investigated their role and feasibility
in TBI, total marrow- (TMI) or total lymphoid irradiation
(TLI) [9-14]. It could be shown that TBI using HT is feas-
ible and offers advantages over the standard LINAC-based
approach. Individual RT-planning allows for better control
over and improvement of dose-distribution on target-
structures and OARs. With the helical beam-delivery one
can increase both conformality and homogeneity in* Correspondence: arne.gruen@charite.de
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reproduction in any medium, provided the ortarget-dose distribution. MV-CT-based guidance provides
image-adapted beam-delivery after correction for patient
movement and set-up errors.
The goal of this study was the establishment of HT-
based TBI at our institute. As of now our standard pro-
cedure for TBI was Linac-based using a translation bunk
and lung attenuators for lung shielding. Using HT for TBI
we strived for individual control over dose-distribution for
optimal target coverage and highly conformal sparing of
organs at risk such as the lungs at the same time to pos-
sibly decrease acute as well as late treatment sequelae
(Figure 1). By shortening overall treatment time patients`
comfort should be enhanced. Because of their limited
body length children and young adults seemed especially
eligible for the technique. To guarantee comparability we
adapted dose fractionation and dose planning-constraints
from our standard LINAC-based TBI-protocol.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Comparison of the dose distribution over the lungs in
an Alderson phantom using either a Linac with lung
attenuators (upper part) or Helical Tomotherapy (lower part).
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Consent
All patients were informed about the treatment and it`s
possible adverse events and about necessary diagnostics
prior to treatment. Written consent by either the patient
himself or parents or legal guardians was obtained in all
cases.Figure 2 Contours: body (green). For the prevention of dose calculation
2 mm (yellow). To prevent underdosing in the case of patient movement d
the body plus an external margin of 10 mm (red). Lung contours (dark blu
created into the lungs to prevent underdosing on the ribs due to respirato
individual internal margin of 0.5-1 cm (light blue). Heart (purple).Positioning/planning-CT
Patients were immobilised in supine position using
customised thermoplastic 3-point masks (Orfit Efficast,
Orfit Industries America, 350 Jericho Turnpike, Suite
101, Jericho, New York 11753) for head support and a
vacuum cradle (Elekta BlueBAGTM, Henderson, NV,
89074) for body support on an adjustable combined
board. Planning CT images (Siemens Somatom Sensa-
tion Open, Siemens Medical Solutions USA, Inc.,
Malvern, PA 19355–1406) were acquired in supine
position with 5 mm slices. In case of patients no lon-
ger than 145 cm in body length, CT images were ac-
quired head-first from the patients’ vertex to the toes.
For localization purposes, fiducial markers (Beekley
CT-SPOTS® Crosshair, Beekley Corporation, Bristol CT
06010, USA) were attached in at least three axial planes:
in the regions of the head, thorax/abdomen and knees.
For patients exceeding 145 cm body length two CT data
sets were acquired. One covered the range between the
patients’ vertex and the lower thigh. In this case apart
from the markers at head and thorax/abdomen, a third fi-
ducial set was placed in the PTV cut plane, which was
assigned to the mid of the upper thigh. The second CT
scan covered the range between the patients’ toes and the
upper thigh. Here the fiducials were placed in the knee
plane and again in the cut plane. After acquisition of the
CTs the position of the fiducial marker was transferred
onto the patient using a felt pen. The marker itself is then
removed. To prevent blurring of the skin marks a trans-
parent foil was applied.
Contouring
For contouring and planning the Varian Eclipse treatment
planning system (TPS), Version 8.8 (Varian Medicalartifacts the PTV1 equals the body contour with an internal margin of
uring treatment a second PTV (PTV2) with minor importance equals
e). Depending on patient and organ size an internal margin has been
ry motion. Lung sparing constraints thus refer to the lungs minus the
Table 1 Planning parameters
Pt. no. Single dose Fractions Total dose Lung sparing y/n Pitch Pitch legs MF MF legs Field width t
1 2 6 12 y 0.43 / 1.5 / 5 1236 s (=20.6 min)
2 2 6 12 y 0.43 / 1.3 / 5 815 s (=13.6 min)
3 2 6 12 y 0.43 0.43 2.1 1.1 5 1812 s (=30.2 min)
4 2 6 12 y 0.3 0.43 2 1.3 5 1791 s (=29.9 min)
5 2 6 12 y 0.3 0.43 2 1.1 5 1851 s (=30.9 min)
6 2 6 12 y 0.45 / 1.22 / 5 916 s (=15.3 min)
7 2 6 12 y 0.35 0.4 2 1.1 5 1738 s (=29.0 min)
8 2 6 12 y 0.3 0.4 2 1.1 5 1723 s (=28.7 min)
9 2 6 12 y 0.3 0.4 2 1.1 5 1649 s (=27.5 min)
10 2 6 12 y 0.4 0.4 2 2 5 2374 s (=39.6 min)
All patients were treated with single doses of 2 Gy applied twice a day with an interfraction interval of at least eight hours on three consecutive days to a total
dose of 12 Gy with lung sparing to a Dmean of 10 Gy and a Dmin of 8 Gy. Pitch values of 0.3-0.45 and modulation factors (MF) of 1.1-2.1 were used. Field width
of 5 cm.
Gruen et al. Radiation Oncology 2013, 8:92 Page 3 of 8
http://www.ro-journal.com/content/8/1/92Systems, Inc., Palo Alto, CA 94304–1038, USA) was used.
To avoid dose calculation artifacts due to proximity of the
body surface we created an inner margin of 2 mm beneath
the outer surface of the body as PTV1 for TBI. To avoid
underdosage of the ribs and the thoracic wall due to re-
spiratory motion we created an additional inner margin of
5–10 mm (depending on patient and thus on organ size)
into the lungs. This resulted in a volume reduction of the
lungs as an OAR (Figure 2). Following lung dose con-
straints refer to the lung subtracted by the individual in-
ternal margin (IM). In case of split treatments the PTV1
ended 2 cm set back from the actual cut plane in both the
upper body and lower body plan to ensure a homoge-
neous dose transition between the upper-and lower body
plans as determined previously in experimental studies on
a cheese phantom. (Data will be presented elsewhere). To
reduce the susceptibility of delivered dose distributions to
setup imperfections and patient motion a virtual air bolus
of 10 mm thickness was added to the patient surface as an
additional target volume (PTV2) with the prescribed dose
of 12 Gy but lower importance (Figure 2).
Dose prescription and fractionation
Dose prescription to the PTV was 2 Gy single doses de-
livered twice a day (BID) with an interfraction interval of
at least eight hours on three consecutive days to a total
dose of 12 Gy. Constraints to be fulfilled were theFigure 3 Standard localization of TLDs: Sternum (1); Axilla right (2); Acoverage of 95% of the PTV1 by 95% of the prescribed
dose (12 Gy) and the suppression of the lung dose to a
mean dose (Dmean) of no more than 10 Gy and a mini-
mum dose (Dmin) of 8 Gy [15]. Planning criteria were
the homogenous coverage of the PTV by the prescribed
dose and dose to the lungs. Dose peaks (hot spots) were
tolerated only if they were located in the bone marrow
or musculature. 3-D data sets with contours were trans-
ferred to the Hi-Art Treatment Planning System (TPS)
(Tomotherapy Inc., Madison, WI 53717–1954 USA) for
planning. Here we could benefit from previous paramet-
ric studies and apply the heuristic rules for planning pa-
rameters (especially for Pitch (PI)) gained there without
carrying out extensive calculations every time (Table 1).
As back-up we generated conventional LINAC-based
TBI plans for all patients. For this purpose additional
CT data-sets in supine and prone position were ac-
quired. These data-sets were used for TBI planning
using templates and resulted in specific values for trans-
lation speed of the bunk and thickness of individual lung
attenuators to suppress the lung dose to a Dmean of ap-
proximately 10 Gy.
Treatment
Since we opted for a one-machine solution to avoid
transfer of the patient to another machine during treat-
ment we divided the PTV of patients with body lengthxilla left (3); Abdomen (4); Upper thigh right (5).









1 1.95 2.09 / 1.81 /
2 / 2.18 2.13 1.91 2.01
3 2.06 2.03 1.9 2.05 3.29
4 2.05 1.97 1.93 / /
5 1.99 2.03 1.88 2.05 2.33
6 / 2.04 2.03 1.94 2.1
7 1.92 1.87 1.96 1.97 2.86
8 2.2 1.89 2.38 2.36 2.29
9 2.29 2.29 2.86 2.28 2.59
10 2.10 2.05 2.04 1.99 3.14
Exemplary data taken from the 1st fraction of each patient. No TLDs used or
TLD-dislocation in some cases without proper values (/). “Upper thigh right”
position equals the cut plane where upper and lower body PTVs meet and
supposed to merge homogenously, 3.29 Gy in patient number 3 and 3.14 Gy
in patient number 10 due to merge of upper and lower plan and consecutive
overdosing in cut plane which was accepted to avoid under-dosing.
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TBI in two successive sessions: (i) head first from ver-
tex to the cut plane and (ii) after repositioning: feet
first from toes to the cut plane. For all other patients
each TBI fraction was delivered in one session. To
guarantee dose build-up on bony structures lying
within close proximity to the skin we put 1 cm water
equivalent flab-material on the hands, sternum and clavi-
cles of the patients.
Quality assurance
For the purpose of quality assurance (QA), two different
procedures of absolute dosimetry were always applied.
On the one hand measurements with an ionization
chamber in the “cheese” phantom and concomitantTable 3 Patients` characteristics
Patient no. Age at treatment (years) Diagnosis Additiona
1 8 ALL BCR
2 4 ALL BCR
3 18 ALL Non-respo
inductio
4 22 AML in CML M-BC
5 18 ALL Recurrence
6 7 ALL Recurrence Biphenoty
7 13 ALL 2nd Recurrence
8 14 ALL Recurrence
9 9 ALL Recurrence
10 12 ALL Recurrence
Patient age ranged from 4–22 years. Most of the patients presented with ALL (acut
with an acute blast crisis (AML: acute myeloic leukemia) in a CML (chronic myeloic
were seen in some case, two patients had had prior radiation therapy. Body lengthmeasurements with thermo- luminescent detectors
(TLDs) at different reference points on the patients’
body (Figure 3 and Table 2).
Positioning/image guidance
Positioning was verified prior to treatment using
megavoltage (MV)-CTs of either the pre-defined cranio-
thoracal or the pelvic area [16]. Additional MV-CTs of
the knee area were needed in lower body plans in pa-
tients receiving a split-plan treatment. Set up errors were
corrected for immediately.
Anesthesia/monitoring
Since for many of the patients the stress level during the pro-
cedure was fairly high due to the strict immobilization and
the long treatment times most of our patients needed either
sedation or anesthesia (using benzodiazepines, propofol or
ketamines in individual dosages). One patient needed general
intubation anesthesia. Sedation and anesthesia were applied
and overseen by pediatric oncologists and anesthetists. Vital
parameters (heart rate, oxygen saturation) during treatment
could be monitored using a pulse oximeter (NellcorTM
OximaxTM N-65TM, Tyco Healthcare Group LP, Nellcor
Puritan Bennett Group, Pleasanton, CA, USA) and the in-
room camera and microphone system (EE811A, Schneider
Intercom GmbH, Erkrath, Germany).
Patients
Ten patients underwent TBI treatment using HT.
Patients´ characteristics and individual risk factors
are shown in Table 3. All patients presented with
high-risk features such as genetic predictors for high
risk of recurrence such as bcr-abl positivity or non-
response to chemotherapy. Five patients had recurrent









pic leukemia / 130




/ 12 Gy Whole Brain 158
/ 18 Gy Whole Brain 152
e lymphoblastic leukemia) in first or second remission, one patient presented
leukemia) Risk factors such as positivity for the bcr-abl gene fusion product
in treatment position (supine, feet outstretched) ranged from 110–180 cm.
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age of 12.9 years of age. The cohort consisted of 6 female
and 4 male patients. Body length in treatment position (su-
pine position, feet outstretched) ranged from 110 – 180 cm.
Apart from mild chemotherapy induced toxicity such as fa-
tigue, loss of appetite or alopecia neither of the patients
presented with excess morbidity going into treatment.
Results
The average dose covering 95% of the target (D95) to the
PTV1 in all ten patients was 11.7 Gy corresponding to aFigure 4 Dose distribution. (a) transverse, coronal and sagittal dose plan
planes of the upper and lower part of a split TBI-plan.mean coverage of the PTV by 97.5% (Figure 4a and b). Ac-
tual average Dmean for the lungs was 9.27 Gy and 9.25 Gy
for left and right lung respectively (Table 4). Correlation be-
tween actual measured doses by TLD and calculated doses
was satisfactory with no under-dosing observed (Tables 2
and 4). Dose peaks of up to 130% of the prescribed dose
were seen in small volumes. All treatment plans were
checked for dose peaks exceeding the prescribed dose
by more than 107%. Dose peaks were accepted if
only small volumes in non-critical target structures were
affected. Beam-on time ranged from 13.6 min to 20.6 min,es of a non-split TBI-plan (b) transverse, coronal and sagittal dose









PTV1 D5 (Gy) PTV1 lower
body D5 (Gy)
Lung L - IM
Dmean (Gy)
Lung R - IM
Dmean (Gy)
1 11.70 / 11.92 / 12.30 / 7.72 7.55
2 11.80 / 12.02 / 12.30 / 8.19 8.00
3 11.70 11.60 12.11 12.11 12.40 12.70 9.14 9.04
4 11.80 11.80 11.93 12.02 12.30 12.20 9.01 9.06
5 11.80 11.80 11.98 12.10 12.30 12.70 9.18 8.94
6 11.60 / 12.06 / 12.70 / 9.63 9.82
7 11.60 11.50 12.10 12.08 12.80 13.30 10.36 10.06
8 11.70 11.70 12.08 12.17 12.60 12.90 9.98 10.12
9 11.80 11.70 12.20 12.14 13.50 13.00 9.71 9.72
10 11.70 11.80 12.00 12.00 12.80 13.00 9.80 10.20
Range 11.60-11.80 11.5-11.8 11.92-12.20 12.02-12.17 12.30-13.50 12.20-13.30 7.72-10.36 7.55-10.12
Average 11.72 11.70 12.04 12.09 12.60 12.83 9.27 9.25
Table 5 Acute toxicity
Pt. no. Grade 1–2 toxicity Grade 3-4
1 Mucositis, Fatigue /
2 Fatigue /




5 Xerostomie, Parotitis, Headache, Fatigue /
6 Loss of appetite, Fatigue, Nausea, Dysgeusia /
7 Loss of appetite, Nausea, Headache, Neck pain /
8 Loss of appetite, Nausea, Fatigue /
9 Xerostomia /
Overall acute toxicity was low with only grade 1–2 morbidity. Grade 3–4
toxicity was not observed. Toxicity scoring by CTCAE v4.0.
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39.6 min (average: 34.2 min) for the split plans. Due to their
body length in treatment position (supine, feet outstretched)
of ≤ 145 cm three patients could be treated with a non-split
TBI plan as compared to seven patients for whom the pro-
cedure had to be split into an upper body- and lower body
plan connecting in the upper thigh area.
Actual overall “in-room”-time (patient going into the
treatment room to patient leaving) regularly exceeded
actual beam-on considerably. The pronounced differ-
ences between net beam-on time and actual overall
treatment time were due to the positioning procedures
including MV-CTs, correction for set-up errors and the
sometimes elaborate anesthetic measures and finally due
to treatment interruptions caused by machine-failure or
down time. Three out of 54 overall fractions had to be
applied LINAC-based due to HT down time. The largest
share of hardware-associated interruptions stemmed
from MLC-errors that could be overwritten without
compromising the treatment. In two patients the treat-
ment had to be prolonged into a fourth day to complete
the treatment.
Most of our patients complained of fatigue, loss of ap-
petite or nausea even before the onset of therapy due to
prior cytotoxic treatment. These symptoms were only
slightly aggravated by TBI. Overall acute morbidity of
TBI was low corresponding to only mild Grade 1 – 2
side effects in all 10 patients, grade 3–4 side effects were
not observed (Table 5).
With 1 to 15 months of follow up eight of ten patients
are in stable remission without further radiation-related
morbidity. One patient died immediately after trans-
plantation due to bacterial sepsis and consecutive multi-
organ failure and a second patient died three month
after transplantation due to uncontrollable graft versus
host disease (GVHD) grade IV.Discussion
In the past decades cure rates in paediatric oncology
have been increased. Especially in those cohorts with
high cure rates and long-term survivors all efforts should
be made with regard to the reduction of acute and
chronic therapy related morbidity. Most authors report
on LINAC-based procedures with a simple technique
using ap/pa portals, although other attempts at treating
the patient over the whole axis using HT, as we did, have
been published [17,18]. The concept of HT for TBI of-
fers advantages over conventional LINAC-based TBI
with higher conformality due to the 360° of beam applica-
tion versus the standard fixed beam approach (Figure 1).
Further it allows for individual sparing of organs at high
risk of radiation induced toxicity such as the lungs. Since
the main goal of this study was to establish HT in TBI at
our institute we used the same fractionation and dose
constraints as in our standard LINAC-based TBI protocol
only adding a minimum dose for the lungs to prevent
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lapses. Highly conformal lung sparing could be achieved
with mean lung doses of no more than 10 Gy. Overall
morbidity during treatment was low corresponding to
only mild grade 1–2 side effects which is in line with the
results seen by other groups such as Schultheiss et al. [11],
grade 3 – 4 side effects were not observed [14]. No lung
toxicity was observed and is still not reported on with up
to 15 months of follow-up.
A disadvantage of HT is the limited translation length
of the table, allowing irradiable PTV lengths of approxi-
mately 145 cm. All patients exceeding 145 cm body
length need a solution concerning the irradiation tech-
nique for the lower part of the body. The interruption of
treatment and shift of the patient from one machine to
another implies discomfort for the patient and is a po-
tential source of QA-problems. That is why we decided
to use a “single-machine”-solution and devised separate
lower body plans for patients with exceeding body
length. Other groups kept the legs of patients with ex-
ceeding body length in a folded position in a vac-loc bag
[9], others are using ap/pa portals of a Linac for TBI and
are applying Helical Tomotherapy Total Marrow Irradi-
ation only as a boost [18].
We could show that TBI using HT is an interdisciplin-
ary challenge, but feasible as a one-machine-solution
even for patients with body length exceeding 145 cm.
Planning constraints derived from conventional LINAC-
based TBI could be fulfilled. We opted for a minimal lung
dose of 8 Gy to prevent underdosing and thus increasing
possible relapse rates [19]. We verified calculated doses by
TLD-measurements on defined localizations during treat-
ment on the patients. Measured doses generally
corresponded well to the calculated doses. No under-
dosing was observed. Dose maxima within the PTV were
acceptable. Set-up errors or patient movement during
treatment of up to 1 cm were anticipated by using a
double PTV concept and creating a second PTV (PTV2)
of 10 mm around the patient, thereby creating a safety
margin where dose would be deposited in case the patient
moved.
A reduction of overall treatment time compared to our
standard LINAC-based TBI approach could not be
achieved. Necessary patient preparation with image guid-
ance and correction for set-up errors, sedation or
anesthesia where necessary added to the complexity of the
procedure and called for increased man-power with not
only radiation oncologists, physicists and radiographers
but sometimes also paediatric oncologists, anesthesists
and their personnel overseeing the treatment. The ele-
vated stress level for the patients caused by the strict
immobilization, the claustrophobic interior of the bore
and the loud machine noise made up some of the draw-
backs of the procedure.Technical difficulties, this mainly being MLC-errors,
further prolonged overall treatment time. Excess main-
tenance could only partly compensate for the problem
thus clearly leaving room for improvement in technical
reliability.
Conclusion
It could be demonstrated that HT allows for excellent tar-
get coverage of the PTV with individual sparing of organs
at risk such as the lungs. Only mild side effects were ob-
served. Longer treatment times and technical difficulties
leave room for further improvements of the technique.
Nevertheless, HT seems to be a promising tool for opti-
mizing radiation therapy in pediatric oncology.
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